American Kidney Fund Announces Support from GSK to Expand Awareness for Underrepresented Community Participation in Clinical Trials | News Direct

American Kidney Fund Announces Support from GSK to Expand Awareness for Underrepresented Community Participation in Clinical Trials

News release by American Kidney Fund

facebook icon linkedin icon twitter icon pinterest icon email icon ROCKVILLE, MD | November 04, 2021 09:00 AM Eastern Daylight Time

The American Kidney Fund (AKF) today announced that GSK has provided continued support to expand upon AKF’s efforts to increase participation of underrepresented communities in clinical trials.

With GSK’s support, AKF will further enhance its clinical trials educational materials, including providing translations for new and existing content for Spanish-speaking audiences. This renewed effort will also include a video series, featuring Black and Hispanic kidney patients discussing their personal experiences as participants in clinical trials.

“People of color, particularly Black and Hispanic individuals, continue to be underrepresented in clinical trial research studies for a number of reasons, which ultimately impacts research outcomes and the ability to uncover new options for patients,” said LaVarne A. Burton, AKF President and CEO. “With GSK’s funding, it is our hope that we can help people of color in their decision-making process when considering signing up for a clinical trial, as well as in speaking with their doctors about how they can be active participants in improving their own health and the future health of others.”

GSK’s funding is a continuation of the support it has provided since 2019 to help AKF build a clinical trials awareness campaign, which supports AKF's broader strategy of addressing disparities and improving health equity in kidney disease care.

“As part of our commitment to inclusion and diversity at GSK, we are ensuring that underrepresented patient populations are well represented in our clinical trials to make certain that our medications are safe and effective in a variety of patient groups,” said Precil Varghese, GSK Senior Medical Lead, Specialty and Pipeline. “We are proud to support AKF in its mission of educating the kidney disease community and historically underserved communities to help prevent and manage kidney disease.”

About the American Kidney Fund

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

 

Contact Details

 

Stefanie Tuck

 

Work:

 

+1 202-470-1797

 

 

Mobile:

 

+1 978-390-1394

 

 

11921 Rockville Pike, Suite 300, Rockville, MD 20852

 

AKF@jpa.com

 

Company Website

 

https://www.kidneyfund.org/